These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication. Caliendo AM; Savara A; An D; DeVore K; Kaplan JC; D'Aquila RT J Virol; 1996 Apr; 70(4):2146-53. PubMed ID: 8642636 [TBL] [Abstract][Full Text] [Related]
24. Human immunodeficiency virus reverse transcriptase. Substrate and inhibitor kinetics with thymidine 5'-triphosphate and 3'-azido-3'-deoxythymidine 5'-triphosphate. Reardon JE; Miller WH J Biol Chem; 1990 Nov; 265(33):20302-7. PubMed ID: 1700787 [TBL] [Abstract][Full Text] [Related]
25. Simultaneous mutations at Tyr-181 and Tyr-188 in HIV-1 reverse transcriptase prevents inhibition of RNA-dependent DNA polymerase activity by the bisheteroarylpiperazine (BHAP) U-90152s. Fan N; Rank KB; Evans DB; Thomas RC; Tarpley WG; Sharma SK FEBS Lett; 1995 Aug; 370(1-2):59-62. PubMed ID: 7544302 [TBL] [Abstract][Full Text] [Related]
26. Nucleoside analog resistance caused by insertions in the fingers of human immunodeficiency virus type 1 reverse transcriptase involves ATP-mediated excision. Boyer PL; Sarafianos SG; Arnold E; Hughes SH J Virol; 2002 Sep; 76(18):9143-51. PubMed ID: 12186898 [TBL] [Abstract][Full Text] [Related]
27. The processivity of DNA synthesis exhibited by drug-resistant variants of human immunodeficiency virus type-1 reverse transcriptase. Avidan O; Hizi A Nucleic Acids Res; 1998 Apr; 26(7):1713-7. PubMed ID: 9512543 [TBL] [Abstract][Full Text] [Related]
28. Recombinant human immunodeficiency virus type 1 reverse transcriptase is heterogeneous. Wilson JE; Wright LL; Martin JL; Haire SE; Ray PH; Painter GR; Furman PA J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Jan; 11(1):20-30. PubMed ID: 8528729 [TBL] [Abstract][Full Text] [Related]
29. Resistance of human immunodeficiency virus type 1 reverse transcriptase to TIBO derivatives induced by site-directed mutagenesis. de Vreese K; Debyser Z; Vandamme AM; Pauwels R; Desmyter J; de Clercq E; Anné J Virology; 1992 Jun; 188(2):900-4. PubMed ID: 1374986 [TBL] [Abstract][Full Text] [Related]
30. Correlation between viral resistance to zidovudine and resistance at the reverse transcriptase level for a panel of human immunodeficiency virus type 1 mutants. Lennerstrand J; Hertogs K; Stammers DK; Larder BA J Virol; 2001 Aug; 75(15):7202-5. PubMed ID: 11435603 [TBL] [Abstract][Full Text] [Related]
31. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. Richman DD; Havlir D; Corbeil J; Looney D; Ignacio C; Spector SA; Sullivan J; Cheeseman S; Barringer K; Pauletti D J Virol; 1994 Mar; 68(3):1660-6. PubMed ID: 7509000 [TBL] [Abstract][Full Text] [Related]
32. Human immunodeficiency virus reverse transcriptase substitutes for DNA polymerase I in Escherichia coli. Kim B; Loeb LA Proc Natl Acad Sci U S A; 1995 Jan; 92(3):684-8. PubMed ID: 7531338 [TBL] [Abstract][Full Text] [Related]
33. Molecular basis for the enantioselectivity of HIV-1 reverse transcriptase: role of the 3'-hydroxyl group of the L-(beta)-ribose in chiral discrimination between D- and L-enantiomers of deoxy- and dideoxy-nucleoside triphosphate analogs. Maga G; Amacker M; Hübscher U; Gosselin G; Imbach JL; Mathé C; Faraj A; Sommadossi JP; Spadari S Nucleic Acids Res; 1999 Feb; 27(4):972-8. PubMed ID: 9927728 [TBL] [Abstract][Full Text] [Related]
34. [Stability of human immunodeficiency virus to azidothymidine. II. Kinetic characteristics of "AZT-resistant" mutant forms of reverse transcriptase]. Pokholok DK; Gudima SO; Memelova LV; Esipov DS; Rechinskiĭ VO; Kochetkov SN Biokhimiia; 1996 Jan; 61(1):142-51. PubMed ID: 8679772 [TBL] [Abstract][Full Text] [Related]
35. Site-specific incorporation of nucleoside analogs by HIV-1 reverse transcriptase and the template grip mutant P157S. Template interactions influence substrate recognition at the polymerase active site. Klarmann GJ; Smith RA; Schinazi RF; North TW; Preston BD J Biol Chem; 2000 Jan; 275(1):359-66. PubMed ID: 10617626 [TBL] [Abstract][Full Text] [Related]
36. Relationship between 3'-azido-3'-deoxythymidine resistance and primer unblocking activity in foscarnet-resistant mutants of human immunodeficiency virus type 1 reverse transcriptase. Meyer PR; Matsuura SE; Zonarich D; Chopra RR; Pendarvis E; Bazmi HZ; Mellors JW; Scott WA J Virol; 2003 Jun; 77(11):6127-37. PubMed ID: 12743270 [TBL] [Abstract][Full Text] [Related]
37. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Tisdale M; Kemp SD; Parry NR; Larder BA Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5653-6. PubMed ID: 7685907 [TBL] [Abstract][Full Text] [Related]
38. Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility. Harrigan PR; Kinghorn I; Bloor S; Kemp SD; Nájera I; Kohli A; Larder BA J Virol; 1996 Sep; 70(9):5930-4. PubMed ID: 8709214 [TBL] [Abstract][Full Text] [Related]
39. Human immunodeficiency virus type 1 reverse transcriptase. 3'-Azidodeoxythymidine 5'-triphosphate inhibition indicates two-step binding for template-primer. Jaju M; Beard WA; Wilson SH J Biol Chem; 1995 Apr; 270(17):9740-7. PubMed ID: 7537269 [TBL] [Abstract][Full Text] [Related]
40. Rapid phenotypic reversion of zidovudine-resistant feline immunodeficiency virus without loss of drug-resistant reverse transcriptase. Remington KM; Zhu YQ; Phillips TR; North TW J Virol; 1994 Feb; 68(2):632-7. PubMed ID: 7507182 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]